Abstract 17P
Background
Breast Cancer is the most common yet preventable & treatable forms of cancer in the Philippines, hence a need to prioritize & strengthen organized screening programs to detect early & bridge to treatment to increase survival. The ACT Now PRIME CARE for Breast Cancer aims to detect breast cancer thru screening using integrated patient online education & self-evaluation with mobile clinic clinical breast exam, ultrasound, navigation to referral pathways for Centers with Medical Access Programs.
Methods
Women ages 40-60, were advised to register at actnow.philcancer.org.ph to access videos on breast health, cancer & self-exam. Patients' self-reported signs, symptoms & risk factors were triaged into high risk & low risk. Immediate scheduling of high-risk individuals to mobile clinic visit were done while low-risk individuals were advised to visit on a yearly basis. Patient education, Clinical Breast Exam & Ultrasound were performed. Both high risk & low risk groups were scheduled for teleconsultation or clinic visits. Suspicious breast findings were referred for immediate biopsy. Confirmed malignancy were referred to centers with medical access programs.
Results
Among women who completed the educational videos, 87% were evaluated to have good comprehension of the materials. Among 1,790 women screened, 277 were clinically high-risk patients & only 6 had breast ultrasound BIRADS 4-5. Two had negative biopsy results. Four had pending biopsy results. Two had confirmed positive early breast malignancy who were subsequently referred treatment. Turnaround time from work-up to treatment was 4 weeks. Among 1513 low risk women, majority have commitments to visit for screening once a year.
Conclusions
In a limited resource country, there's a need to strengthen community-based cancer screening, strengthen patient navigation & improve patients' awareness on available financial & medical access programs to improve compliance & survival. The ACT Now PRIME CARE is a pilot program to enhance education about breast health & cancer, capture cases in the community & provide immediate referral pathways to improve outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Philippine Cancer Society.
Funding
Philippine Cancer Society.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
271P - Prostate cancer with histone modifier UTX mutations can benefit from olaparib
Presenter: NOBUHITO MURAMOTO
Session: Poster Display
Resources:
Abstract
272P - Comparison between MRI-targeted and standard biopsy for prostate cancer detection: A systematic review and meta-analysis
Presenter: Andree Kurniawan
Session: Poster Display
Resources:
Abstract
273P - The diagnostic performance of cognitive MRI-targeted biopsy in biopsy-naïve patients undergoing systematic 14-region 18-core biopsy: Do the three areas affect the results?
Presenter: Yuka Toyama
Session: Poster Display
Resources:
Abstract
274P - Index tumor location influencing early biochemical recurrence after radical prostatectomy in patients with negative surgical margins
Presenter: Jun Akatsuka
Session: Poster Display
Resources:
Abstract
275P - Prognosis of metastatic castration-resistant prostate cancer in response to chemotherapy and PSMA expression in circulating tumor cells
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
276P - Prognostic significance of p53 mutation in metastatic hormone-sensitive prostate cancer
Presenter: Lakshmi Kamala
Session: Poster Display
Resources:
Abstract
277P - Vasohibin-1 expression as a biomarker of aggressive growth in prostate ductal adenocarcinoma
Presenter: Murad Salomov
Session: Poster Display
Resources:
Abstract
278P - Full-coverage radiotherapy for prostate cancer patients with oligometastases
Presenter: Bichun Xu
Session: Poster Display
Resources:
Abstract
279P - Hypofractionated radiotherapy protocol implementation and early outcomes for prostate cancer patients: A single institution retrospective review
Presenter: Thu Nguyen
Session: Poster Display
Resources:
Abstract
280P - Radium-223 for patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases progressing after first-line abiraterone or enzalutamide: One institutional experience
Presenter: Keng Man Chiang
Session: Poster Display
Resources:
Abstract